Last $22.62 USD
Change Today +0.52 / 2.35%
Volume 65.6K
QDEL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 05/24/13 All times are local (Market data is delayed by at least 15 minutes).

quidel corp (QDEL) Snapshot

Open
$22.04
Previous Close
$22.10
Day High
$22.89
Day Low
$22.04
52 Week High
03/6/13 - $24.95
52 Week Low
08/2/12 - $14.92
Market Cap
763.0M
Average Volume 10 Days
128.6K
EPS TTM
$0.51
Shares Outstanding
33.7M
EX-Date
--
P/E TM
44.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for QUIDEL CORP (QDEL)

Related News

No related news articles were found.

quidel corp (QDEL) Related Businessweek News

No Related Businessweek News Found

quidel corp (QDEL) Details

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, women’s health, and gastrointestinal diseases. The company’s products for infectious diseases include QuickVue influenza test to detect viral antigens of influenza type A and B; QuickVue Strep A tests to detect Group A Streptococcal antigen from throat swabs or confirmation of presumptive Group A Streptococcal colonies recovered from culture; QuickVue RSV test, a rapid immunoassay for respiratory syncitial virus; and cell culture and DFA detection solutions to detect seven viral respiratory pathogens. It also offers cell-based products in various formats, including tubes, shell vials, and multi-well plates to culture and test for human viruses; ELVIS HSV system for the isolation and detection of herpes simplex virus (HSV) types 1 and 2; and a multiplex cell culture solution to isolate HSV, varicella zoster virus, and cytomegalovirus, as well as provides various analyzers and molecular assays. The company’s products for women’s health consist of QuickVue and RapidVue pregnancy tests to detect human chorionic gonoadotropin in serum or urine for the early detection of pregnancy; Thyretain for the diagnosis of graves, an autoimmune disease; QuickVue Chlamydia test to detect chlamydia trachomatis from endocervical swab and cytology brush specimens; and clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation, including metabolic bone markers to monitor the effectiveness of therapy in pharmaceutical and related research. In addition, it provides a fecal immunochemical test to detect the presence of blood in stool specimens; indirect fluorescent antibody products; and Helicobacter pylori tests, as well as develops diagnostic and research products in the fields of oncology, bone health, and autoimmune diseases. The company was founded in 1979 and is headquartered in San Diego, California.

514 Employees
Last Reported Date: 02/22/13
Founded in 1979

quidel corp (QDEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $494.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $302.5K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $292.8K
Senior Vice President of Business Development...
Total Annual Compensation: $319.2K
Chief Scientific Officer
Total Annual Compensation: $306.8K
Compensation as of Fiscal Year 2012.

quidel corp (QDEL) Key Developments

Quidel Corporation Provides Tax Rate Guidance for the Year 2013

Quidel Corporation provided tax rate guidance for the year 2013. For the year, the company estimated effective tax rate to be in the range of 30% to 32%.

Quidel Corp. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013

Quidel Corp. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. Total revenues for the first quarter of 2013 were $62.0 million as compared to $38.0 million in the first quarter of 2012. The increase in Revenue was driven by greater sales of infectious disease products due to a stronger influenza and respiratory disease season, as compared to the first quarter of 2012. Net income for the first quarter of 2013 was $12.4 million, or $0.36 per diluted share, compared to $0.05 million, or $0.00 per diluted share, for the first quarter of 2012. On a non-GAAP basis, excluding amortization of intangibles and stock compensation expense, net income for the first quarter of 2013 was $17.0 million, or $0.49 per diluted share, compared to $3.7 million, or $0.11 per diluted share, for the same period in 2012. Operating income was $17,189,000 against $470,000 a year ago. Income before taxes was $16,991,000 against $81,000 a year ago.

Quidel Corp. to Report Q1, 2013 Results on Apr 23, 2013

Quidel Corp. announced that they will report Q1, 2013 results at 5:00 PM, Eastern Standard Time on Apr 23, 2013

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QDEL:US $22.62 USD +0.52

QDEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $3.67 USD -0.01
Haemonetics Corp $41.08 USD -0.20
Ion Beam Applications €5.54 EUR 0.00
Meridian Bioscience Inc $21.89 USD +0.23
Response Biomedical Corp C$3.48 CAD +0.38
View Industry Companies
 

Industry Analysis

QDEL

Industry Average

Valuation QDEL Industry Range
Price/Earnings 44.6x
Price/Sales 4.2x
Price/Book 3.5x
Price/Cash Flow 31.4x
TEV/Sales 4.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUIDEL CORP, please visit www.quidel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.